The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 05 2019
Historique:
received: 08 08 2018
accepted: 03 05 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 21 10 2020
Statut: epublish

Résumé

Improved understanding of the molecular mechanisms responsible for the progression from a "non-pathogenic" steatotic state to Non-Alcoholic Steatohepatitis is an important clinical requirement. The cell death-inducing DFF45 like effector (CIDE) family members (A, B and FSP27) regulate hepatic lipid homeostasis by controlling lipid droplet growth and/or VLDL production. However, CIDE proteins, particularly FSP27, have a dual role in that they also regulate cell death. We here report that the hepatic expression of CIDEA and FSP27 (α/β) was similarly upregulated in a dietary mouse model of obesity-mediated hepatic steatosis. In contrast, CIDEA expression decreased, but FSP27-β expression strongly increased in a dietary mouse model of steatohepatitis. The inverse expression pattern of CIDEA and FSP27β was amplified with the increasing severity of the liver inflammation and injury. In obese patients, the hepatic CIDEC2 (human homologue of mouse FSP27β) expression strongly correlated with the NAFLD activity score and liver injury. The hepatic expression of CIDEA tended to increase with obesity, but decreased with NAFLD severity. In hepatic cell lines, the downregulation of FSP27β resulted in the fractionation of lipid droplets, whereas its overexpression decreased the expression of the anti-apoptotic BCL2 marker. This, in turn, sensitized cells to apoptosis in response to TNF α and saturated fatty acid. Considered together, our animal, human and in vitro studies indicate that differential expression of FSP27β/CIDEC2 and CIDEA is related to NAFLD progression and liver injury.

Identifiants

pubmed: 31097771
doi: 10.1038/s41598-019-43928-7
pii: 10.1038/s41598-019-43928-7
pmc: PMC6522528
doi:

Substances chimiques

Apoptosis Regulatory Proteins 0
BCL2 protein, human 0
CIDEA protein, human 0
CIDEB protein, human 0
CIDEC protein, human 0
Proto-Oncogene Proteins c-bcl-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7501

Références

Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1395-413
pubmed: 19843876
Biol Pharm Bull. 2013;36(11):1766-72
pubmed: 24189421
Am J Physiol Endocrinol Metab. 2008 Apr;294(4):E654-67
pubmed: 18198355
Hepatology. 2007 Jun;45(6):1366-74
pubmed: 17476695
Obesity (Silver Spring). 2010 Feb;18(2):417-9
pubmed: 19661960
J Lipid Res. 2012 Sep;53(9):1877-89
pubmed: 22661308
EMBO J. 1998 May 1;17(9):2526-33
pubmed: 9564035
Mol Biosyst. 2011 Jan;7(1):91-100
pubmed: 20967381
J Biol Chem. 2003 Jan 3;278(1):498-505
pubmed: 12401792
PLoS One. 2011 Mar 18;6(3):e17599
pubmed: 21445263
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
PLoS One. 2011;6(12):e28614
pubmed: 22194867
Cell Metab. 2009 Feb;9(2):177-90
pubmed: 19187774
Cell Death Dis. 2014 May 08;5:e1208
pubmed: 24810044
Biochem J. 2010 Sep 1;430(2):245-54
pubmed: 20575761
Eur Heart J. 2012 May;33(10):1279-89
pubmed: 21825308
Hepatology. 2012 Jul;56(1):95-107
pubmed: 22278400
Cell Metab. 2018 Jan 9;27(1):22-41
pubmed: 28867301
Acta Biochim Biophys Sin (Shanghai). 2011 Oct;43(10):779-86
pubmed: 21865223
PLoS One. 2010 Oct 22;5(10):e13577
pubmed: 21042596
Diabetes. 2005 Oct;54(10):3032-4
pubmed: 16186410
Metabolism. 2008 Apr;57(4):502-5
pubmed: 18328351
Gastroenterology. 2015 Oct;149(4):1030-41.e6
pubmed: 26099526
Hepatology. 2015 Mar;61(3):857-69
pubmed: 25125366
Diabetes. 2007 Oct;56(10):2523-32
pubmed: 17646209
Front Biosci. 2005 Sep 01;10:3093-9
pubmed: 15970563
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82
pubmed: 12629214
Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95
pubmed: 27432073
J Lipid Res. 2017 Nov;58(11):2127-2138
pubmed: 28874443
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Aliment Pharmacol Ther. 2010 Dec;32(11-12):1315-22
pubmed: 21050233
J Biol Chem. 2011 Jun 24;286(25):22195-202
pubmed: 21521693
J Hepatol. 2010 Oct;53(4):724-31
pubmed: 20655124
Cell Metab. 2008 Apr;7(4):302-11
pubmed: 18396136
J Clin Transl Hepatol. 2015 Mar;3(1):9-16
pubmed: 26356325
J Hepatol. 2017 Aug;67(2):328-338
pubmed: 28323124
Am J Gastroenterol. 2004 Sep;99(9):1708-17
pubmed: 15330907
Hepatology. 2001 Dec;34(6):1158-63
pubmed: 11732005

Auteurs

Arnaud Sans (A)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Stéphanie Bonnafous (S)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Déborah Rousseau (D)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.

Stéphanie Patouraux (S)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Clémence M Canivet (CM)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Pierre S Leclere (PS)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.

Jeanne Tran-Van-Nhieu (J)

HU Henri Mondor, Department of Pathology, AP-HP - Université Paris Est Créteil, Créteil, France.

Carmelo Luci (C)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.

Béatrice Bailly-Maitre (B)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.

Xu Xu (X)

Weill Cornell Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, New York, USA.

Ann-Hwee Lee (AH)

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, USA.

Kaori Minehira (K)

University of Lausanne, Department of Physiology, Lausanne, Switzerland.

Rodolphe Anty (R)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Albert Tran (A)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Antonio Iannelli (A)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Université Côte d'Azur, CHU, INSERM, U1065, C3M, Nice, France.

Philippe Gual (P)

Université Côte d'Azur, INSERM, U1065, C3M, Nice, France. philippe.gual@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH